Weekly Research Analysts’ Ratings Changes for BlossomHill Therapeutics (BLSM)

Several brokerages have updated their recommendations and price targets on shares of BlossomHill Therapeutics (NASDAQ: BLSM) in the last few weeks:

• 9/2/2026 – BlossomHill Therapeutics was upgraded by Zacks Research to “hold”.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $30.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $35.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $35.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $30.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Lifesci Capital. They set an “outperform” rating and a $32.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $28.00 price target on the stock.
• 8/15/2026 – BlossomHill Therapeutics was upgraded by Wall Street Zen to “hold”.

Insiders Place Their Bets

In other BlossomHill Therapeutics news, General Counsel Vincent Liptak acquired 2,200 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $35,200.00. Following the completion of the transaction, the general counsel directly owned 111,412 shares in the company, valued at $1,782,592. This trade represents a 2.01% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Orbimed Advisors Llc bought 625,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the transaction, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This represents a 29.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 1,573,900 shares of company stock worth $25,181,900 in the last 90 days.

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.